Patients with HER2–/HR+ BC had the most favorable age-standardized net survival among all BC subtypes, with 1-year net survival exceeding 99% and 5-year survival exceeding 92% in all diagnostic periods (Figure 4A). The gene discussed is ERBB2; the disease is breast cancer.